Oncotarget

Research Papers:

Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells

Jiajia Liu, Qinglai Tang _, Shisheng Li and Xinming Yang

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:86446-86456. https://doi.org/10.18632/oncotarget.13424

Metrics: PDF 1634 views  |   HTML 1928 views  |   ?  


Abstract

Jiajia Liu1, Qinglai Tang1, Shisheng Li1, Xinming Yang1

1Department of Otolaryngology, Head and Neck Surgery, the Second Xiangya Hospital, Central South University, Changsha 410011, China

Correspondence to:

Qinglai Tang, email: [email protected]

Keywords: laryngeal cancer stem cells, microRNA-125a, HAX-1, cisplatin, chemoresistance

Received: October 21, 2016     Accepted: November 07, 2016     Published: November 17, 2016

ABSTRACT

Chemoresistance is a major obstacle in chemotherapy of laryngeal carcinoma. Recently, studies indicate that cancer stem cells are responsible for chemotherapy failure. In addition, microRNAs play important roles in tumor initiation, development and multidrug resistance. In the present study, we found that the expression of microRNA-125a was decreased in laryngeal carcinoma tissues and Hep-2 laryngeal cancer stem cells (Hep-2-CSCs). MicroRNA-125a gain-of-function significantly increased the sensitivity of Hep-2-CSCs to cisplatin in vitro and in vivo. Combination with microRNA-125a mimics can decrease the half maximal inhibitory concentration of Hep-2-CSCs to cisplatin. Mechanically, we found that microRNA-125a reverses cisplatin resistance in Hep-2-CSCs by targeting Hematopoietic cell-specific protein 1-associated protein X-1 (HAX-1). Inhibition of HAX-1 by microRNA-125a significantly promotes the cisplatin-induced apoptosis in Hep-2-CSCs through mitochondrial pathway. In addition, multidrug resistance of Hep-2-CSCs to vincristine, etoposide and doxorubicin was greatly improved after the cells were transfected with microRNA-125a mimics. These dates strongly suggested the promotion of microRNA-125a/HAX-1 axis on chemotherapy of laryngeal carcinoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13424